Selenia nears FDA approval
The FDA issued Hologic an approvable letter in mid-July for its Lorad Selenia digital mammography system. The full-field product is based on an amorphous selenium detector plate developed by Direct Radiography, which Hologic purchased three years ago.
The FDA issued Hologic an approvable letter in mid-July for its Lorad Selenia digital mammography system. The full-field product is based on an amorphous selenium detector plate developed by Direct Radiography, which Hologic purchased three years ago. The letter, issued in response to a premarket approval application, is the last step before the product is formally accepted by the FDA for sale in the U.S. The letter indicates that the agency will likely allow marketing of Selenia for soft- as well as hard-copy reading. Hologic already has an FDA-approved full-field system, the Lorad Digital Breast Imager. This product, which the FDA approved in March, depends on a charge-coupled detector. Selenia, which uses a more sophisticated direct capture detector, will make this older system obsolete, according to the company.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
